A Phase 2 Study of Osimertinib for Advanced NSCLC with Malignant Pleural Effusion Harboring EGFR T790M mutation
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
Price : $35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Feb 2018 Status changed from recruiting to discontinued.
- 24 Aug 2017 Status changed from not yet recruiting to recruiting.
- 30 Mar 2017 New trial record